FOLH1 and neoplasm: The tumor-targeted radioligand 177Lu-PSMA-617 has recently demonstrated anti-tumor activity in prostate cancer [162], and its synergy with anti–PD-1 is currently being investigated in a phase II trial (NCT03805594).